Literature DB >> 9012832

Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region.

D Drabek1, S Raguz, T P De Wit, G M Dingjan, H F Savelkoul, F Grosveld, R W Hendriks.   

Abstract

Bruton tyrosine kinase (Btk) is essential for the development of pre-B cells to mature B cell stages. Btk-deficient mice manifest an X-linked immunodeficiency (xid) defect characterized by a reduction of peripheral IgMlow IgDhigh B cells, a lack of peritoneal CD5+ B cells, low serum levels of IgM and IgG3, and impaired responses to T cell independent type II (TI-II) antigens. We have generated transgenic mice in which expression of the human Btk gene is driven by the murine class II major histocompatibility complex Ea gene locus control region, which provides gene expression from the pre-B cell stage onwards. When these transgenic mice were mated onto a Btk- background, correction of the xid B cell defects was observed: B cells differentiated to mature IgMlowIgDhigh stages, peritoneal CD5+ B cells were present, and serum Ig levels and in vivo responses to TI-II antigens were in the normal ranges. A comparable rescue by transgenic Btk expression was also observed in heterozygous Btk+/- female mice in those B-lineage cells that were Btk-deficient as a result of X chromosome inactivation. These findings indicate that the Btk- phenotype in the mouse can be corrected by expression of human Btk from the pre-B cell stage onwards.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012832      PMCID: PMC19561          DOI: 10.1073/pnas.94.2.610

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Aberrant B cell development and immune response in mice with a compromised BCR complex.

Authors:  R M Torres; H Flaswinkel; M Reth; K Rajewsky
Journal:  Science       Date:  1996-06-21       Impact factor: 47.728

Review 2.  Vertebrate non-receptor protein-tyrosine kinase families.

Authors:  K Neet; T Hunter
Journal:  Genes Cells       Date:  1996-02       Impact factor: 1.891

3.  Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage.

Authors:  R W Hendriks; M F de Bruijn; A Maas; G M Dingjan; A Karis; F Grosveld
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

4.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

Review 5.  The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunity.

Authors:  I Scher
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

6.  Demonstration of B-cell maturation in X-linked immunodeficient mice by simultaneous three-colour immunofluorescence.

Authors:  R R Hardy; K Hayakawa; D R Parks; L A Herzenberg
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

7.  B-cell subpopulations identified by two-colour fluorescence analysis.

Authors:  R R Hardy; K Hayakawa; J Haaijman; L A Herzenberg
Journal:  Nature       Date:  1982-06-17       Impact factor: 49.962

8.  B lymphocyte production in the bone marrow of mice with X-linked immunodeficiency (xid).

Authors:  G K Reid; D G Osmond
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

9.  BTKbase, mutation database for X-linked agammaglobulinemia (XLA).

Authors:  M Vihinen; T Iwata; C Kinnon; S P Kwan; H D Ochs; I Vorechovský; C I Smith
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

10.  Unbalanced X chromosome mosaicism in B cells of mice with X-linked immunodeficiency.

Authors:  M H Nahm; J W Paslay; J M Davie
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  6 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase.

Authors:  G M Dingjan; A Maas; M C Nawijn; L Smit; J S Voerman; F Grosveld; R W Hendriks
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

3.  Btk dosage determines sensitivity to B cell antigen receptor cross-linking.

Authors:  A B Satterthwaite; H Cheroutre; W N Khan; P Sideras; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

5.  Bruton's Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia.

Authors:  Alexander P de Porto; Zhe Liu; Regina de Beer; Sandrine Florquin; Joris J T H Roelofs; Onno J de Boer; Joke M M den Haan; Rudi W Hendriks; Cornelis van 't Veer; Tom van der Poll; Alex F de Vos
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

Review 6.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.